NZ335577A - use of CD40 binding proteinsr stimulating an immune response - Google Patents

use of CD40 binding proteinsr stimulating an immune response

Info

Publication number
NZ335577A
NZ335577A NZ335577A NZ33557796A NZ335577A NZ 335577 A NZ335577 A NZ 335577A NZ 335577 A NZ335577 A NZ 335577A NZ 33557796 A NZ33557796 A NZ 33557796A NZ 335577 A NZ335577 A NZ 335577A
Authority
NZ
New Zealand
Prior art keywords
immune response
stimulating
mammal
binding
proteinsr
Prior art date
Application number
NZ335577A
Inventor
Mary K Kennedy
Mark Alderson
Kim A Campbell
Charles R Maliszewski
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Priority claimed from NZ305083A external-priority patent/NZ305083A/en
Publication of NZ335577A publication Critical patent/NZ335577A/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A CD40 binding protein is used in the manufacture of a medicament for: a) stimulating cell mediated TH1 immune response in a mammal; b) stimulating macrophages to secrete interleukin-12 in a mammal; c) treating a mammal afflicted with a depressed cellular immune response in order to stimulate a cellular immune response and d) stimulating anti-tumour activity in macrophages in a mammal afflicted with a tumour. The CD binding protein can be a CD40 ligand or monoclonal antibodies that specifically bond CD40.
NZ335577A 1995-03-01 1996-02-29 use of CD40 binding proteinsr stimulating an immune response NZ335577A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39623095A 1995-03-01 1995-03-01
NZ305083A NZ305083A (en) 1995-03-01 1996-02-29 Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response

Publications (1)

Publication Number Publication Date
NZ335577A true NZ335577A (en) 2000-09-29

Family

ID=26651708

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ335577A NZ335577A (en) 1995-03-01 1996-02-29 use of CD40 binding proteinsr stimulating an immune response

Country Status (1)

Country Link
NZ (1) NZ335577A (en)

Similar Documents

Publication Publication Date Title
IL92382A0 (en) Immunotherapy involving cd28 stimulation
NZ506214A (en) Therapy for alpha-galactosidase A deficiency
ZA895372B (en) Monoclonal antibodies reactive with cachectin
EP0585943A3 (en) Soluble ligands for cd40
IL83012A0 (en) Immunoconjugates for use in tumor therapy and their production
IL63927A0 (en) Production of silane modified copolymers of alkylene-alkyl acrylates,polysiloxanes having combined therein organo-titanates and the use thereof in the production of silane modified copolymers of alkylenealkyl acrylates
LV11624A (en) Imunstimulejosas monoklonalas antivielas
GB2116424B (en) Water soluable glass articles, their manufacture, and their use in the treatment of ruminant animals
MY106507A (en) Antibody antagonists of human interleukin-4
ZA844377B (en) The effect of human tumor necrosis factor and human interferon and human cancer cells and methods
GR3032660T3 (en) Lymphokine gene therapy of cancer.
JPS54141443A (en) Heat insulating layer that use foaming body particle* bonding material and treatment aid as bases
GB8805792D0 (en) Medicaments
OA07412A (en) Benzoazacycloalhyl-spiro-imidazolidines their preparation and their application in therapy.
MTP924B (en) Homogenous human immune interferom and process therefor
NZ228837A (en) Tumour associated antigen and the monoclonal antibody reactive with it useful in diagnosing and treating cancer
IL61641A0 (en) Immunological detection of human cancer cells and antigens and antibodies for use therein
NZ335577A (en) use of CD40 binding proteinsr stimulating an immune response
EP0202642A3 (en) Process for the in vitro immunization of human splenocytes against tumor associated antigens
GB2098478B (en) Propioibacteria preparations for use in the treatment of tumours
EP0160486A3 (en) Monoclonal antibodies
EP0083439A3 (en) 4-sulfido-oxaza phosphorines and their use in the treatment of cancer, and in immunosuppression
AU517665B2 (en) N-glucofuranosid-6-yl-n3-nitroso-ureas and their use in the treatment of tumours and leukaemia
ZA904229B (en) Monoclonal antibody reactive to a unique antigen widely present on various human leukemia and lymphoma cells and methods of using same for diagnosis and treatment
ES8600518A1 (en) TGF polypeptides, antigenic oligopeptides derived therefrom and antibodies produced therefrom.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired